A Single-arm, Non-randomized and Open-label Phase 3 Study Evaluating the Efficacy, Safety and Tolerability of Intravitreal Aflibercept in Japanese Patients With Neovascular Glaucoma (NVG)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Dec 2020 Results published in the Advances in Therapy
27 Mar 2020 According to a Bayer media release, the company announced that Bayer Yakuhin has received approval for the additional indication of neovascular glaucoma for the intravitreal VEGF inhibitor EYLEAsolution for intravitreal injection 40 mg/mL. This approval is based on the data from two Phase III studies (VEGA and VENERA).
18 Feb 2020 Primary endpoint (Change in IOP (intraocular pressure) from baseline to Week 1) has been met as per results published in the ClinicalTrials.gov Trial Registry

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com